Literature DB >> 3394579

Pharmacological control of the histamine H2 receptor-adenylate cyclase system by famotidine and ranitidine in normal and cancerous human gastric epithelia.

D Fagot1, S Emami, E Chastre, W Bawab, C Gespach.   

Abstract

In human fundic glands, famotidine was about 17 times more potent than ranitidine as an inhibitor of histamine - stimulated cAMP generation. This H2-receptor antagonist had no effect on the receptor-adenylate cyclase systems sensitive to PGE2, isoproterenol (beta 2-receptor), VIP and on forskolin-induced activation of the Gs/catalytic units of the membrane-bound enzyme prepared from human fundic glands. In the HGT-1 human gastric cancer cell line, famotidine and ranitidine showed long lasting, irreversible actions probably related to a slow rate of dissociation from the histamine H2-receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3394579     DOI: 10.1007/bf02142568

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  7 in total

1.  Irreversible and specific inactivation by AH 22216 of histamine H2 receptors in the human gastric cancer cell line HGT-1.

Authors:  I Menez; C Gespach; S Emami; G Rosselin
Journal:  Biochem Biophys Res Commun       Date:  1983-10-14       Impact factor: 3.575

2.  Regulation by vasoactive intestinal peptide of cyclic AMP accumulation in gastric epithelial glands. A characteristic of human stomach.

Authors:  C Dupont; C Gespach; B Chenut; G Rosselin
Journal:  FEBS Lett       Date:  1980-04-21       Impact factor: 4.124

3.  Beta-adrenergic regulation of cyclic adenosine 3',5' monophosphate accumulation in human gastric epithelial glands. Inhibitory effect of somatostatin.

Authors:  N Boige; C Dupont; B Chenut; C Gespach; G Rosselin
Journal:  Eur J Clin Invest       Date:  1984-02       Impact factor: 4.686

4.  Histamine and VIP interactions with receptor-cyclic AMP systems in the human gastric cancer cell line HGT-1.

Authors:  S Emami; C Gespach; M E Forgue-Lafitte; Y Broer; G Rosselin
Journal:  Life Sci       Date:  1983-08-01       Impact factor: 5.037

5.  Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.

Authors:  J M Howard; A N Chremos; M J Collen; K E McArthur; J A Cherner; P N Maton; C A Ciarleglio; M J Cornelius; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

6.  Characterization of a newly established human gastric cancer cell line HGT-1 bearing histamine H2-receptors.

Authors:  C L Laboisse; C Augeron; M H Couturier-Turpin; C Gespach; A M Cheret; F Potet
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

7.  Pharmacology of histamine H2 receptor antagonists in the human gastric cancer cell line HGT-1. Structure-activity relationship of isocytosine-furan and imidazole derivatives related to cimetidine.

Authors:  S Emami; C Gespach
Journal:  Biochem Pharmacol       Date:  1986-06-01       Impact factor: 5.858

  7 in total
  4 in total

Review 1.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  Characterization of histamine H2-receptors in human neutrophils with a series of guanidine analogues of impromidine. Are cell type-specific H2-receptors involved in the regulation of NADPH oxidase?

Authors:  R Burde; A Buschauer; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

3.  Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies.

Authors:  C Bergmann; A Sarem-Aslani; D Ratge; P Fritz; S Walker; H Wisser; U Klotz
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

4.  Absence of antibodies stimulating H2-receptor mediated cyclic adenosine monophosphate (cAMP) production in peptic ulcer disease.

Authors:  A Sarem-Aslani; C Bergmann; S Walker; D Ratge; U Klotz; H Wisser
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.